Middle East and Africa Vascular Stent Market Research Report – Segmented By Product (Peripheral Stents, Coronary Stents, EVAR Stent Grafts), Type, Mode of Delivery, Material, End-user, Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Size From 2024 to 2033
The Middle East and Africa Vascular Stent Market is anticipated to rise from USD 1.96 billion to USD 4.21 billion in 2033, growing at a CAGR of 8.9%.
peripheral arteries. These stents are deployed during angioplasty procedures to restore blood flow in patients suffering from conditions such as coronary artery disease (CAD), peripheral artery disease (PAD), and aneurysms. The market includes a range of stent types such as bare-metal stents, drug-eluting stents, and bioresorbable vascular scaffolds, catering to both elective and emergency cardiovascular interventions.
The region’s market dynamics are shaped by a growing burden of cardiovascular diseases, increasing urbanization, and improvements in healthcare infrastructure, particularly in countries like Saudi Arabia, South Africa, and the United Arab Emirates. According to the World Health Organization (WHO), cardiovascular diseases account for nearly 35% of non-communicable disease-related deaths in the Middle East and over 10% in sub-Saharan Africa, indicating a significant and rising clinical need.
As per the World Bank, healthcare expenditure in the Gulf Cooperation Council (GCC) countries has increased by over 40% in the past decade, supporting the expansion of cardiology services and interventional procedures. Meanwhile, in sub-Saharan Africa, the expansion of private healthcare and increased investment in medical tourism have contributed to improved access to vascular interventions. There has been an increase in hospital-based cardiovascular care in selected African countries over the last five years. Despite these developments, affordability, regulatory fragmentation, and uneven healthcare access remain persistent challenges across the MEA region.
The increasing prevalence of cardiovascular diseases (CVDs), particularly in the Gulf and North African countries, is one of the primary drivers of the MEA Vascular Stent Market. As per the Global Burden of Disease Study 2021, ischemic heart disease is the leading cause of death in the Middle East, responsible for a significant portion of all fatalities in countries such as Saudi Arabia and Egypt. In sub-Saharan Africa, as per the World Health Organization (WHO), CVD-related deaths have risen by nearly 40% since 2010, driven by lifestyle changes, rising obesity rates, and an aging population.
The growing burden of hypertension, diabetes, and hyperlipidemia has further contributed to the rise in vascular diseases. These conditions are significant risk factors for coronary artery disease and peripheral vascular disease, increasing the demand for stent-based interventions. In response, healthcare providers and governments are expanding access to interventional cardiology services, thereby driving the adoption of vascular stents in both public and private healthcare settings.
The rapid expansion of healthcare infrastructure, particularly in the Gulf Cooperation Council (GCC) countries is another key driver of the MEA Vascular Stent Market. Over the past decade, nations such as the United Arab Emirates, Qatar, and Saudi Arabia have significantly invested in building world-class hospitals, catheterization labs, and specialized cardiovascular centers.
Additionally, the growth of medical tourism in the Gulf has contributed to increased demand for high-quality vascular interventions. As per the Dubai Health Authority, over 500,000 medical tourists visited the UAE in 2022, many seeking advanced cardiovascular treatments including stent implantation. Saudi Arabia and Bahrain have also launched national health strategies aimed at attracting international patients by offering cutting-edge medical services. The expansion of private healthcare providers and the availability of advanced stent technologies have further supported this trend.
The high cost of advanced stent technologies, particularly drug-eluting stents (DES) and bioresorbable vascular scaffolds (BVS), is a major restraint in the MEA Vascular Stent Market. While these stents offer superior clinical outcomes, their elevated price points limit widespread adoption, especially in low- and middle-income countries across Africa and parts of the Middle East. According to the World Health Organization (WHO), out-of-pocket healthcare expenditures in many African nations exceed 50%, making high-cost medical devices inaccessible to a large portion of the population.
In countries like Egypt, Nigeria, and Sudan, where public health coverage is limited, patients often rely on out-of-pocket payments or private insurance for vascular interventions. As per the African Development Bank, nearly 60% of cardiovascular procedures in sub-Saharan Africa are paid for directly by patients, significantly restricting the use of premium stent types. Even in the Gulf region, where healthcare spending is higher, budget constraints in public hospitals often lead to the preferential use of bare-metal stents over more expensive alternatives
The shortage of skilled interventional cardiologists and inadequate catheterization lab (cath lab) infrastructure, particularly in sub-Saharan Africa, is another significant challenge in the MEA Vascular Stent Market. According to the Pan African Society of Cardiology (PASCAR), there is a severe disparity in the availability of interventional cardiology services across the continent. In many African countries, there are fewer than 0.1 interventional cardiologists per million people, compared to over 2 per million in Gulf countries.
The World Bank reports that as of 2023, less than 15% of hospitals in sub-Saharan Africa are equipped with cath labs, with most concentrated in major urban centers like Johannesburg, Nairobi, and Lagos. This results in long waiting times and limited access to life-saving procedures such as angioplasty and stent implantation for a large portion of the population. In countries like Ethiopia and Malawi, the lack of cath labs in public hospitals forces patients to seek treatment in the private sector or abroad, significantly increasing the financial burden. Additionally, the training and certification process for interventional cardiologists remains limited and uneven across countries, further exacerbating the human resource gap.
The increasing adoption of digital health and telemedicine platforms to enhance cardiovascular care delivery is a growing opportunity in the MEA Vascular Stent Market. As the region grapples with uneven healthcare access, especially in rural and underserved areas, digital health solutions are playing a pivotal role in improving post-operative monitoring and long-term management of patients with implanted vascular stents.
The integration of remote patient monitoring (RPM) systems with cardiovascular care enables physicians to track stent performance, detect complications early, and manage risk factors such as hypertension and diabetes more effectively. Additionally, digital platforms are facilitating data collection and analysis, which supports the development of personalized treatment plans and improves procedural success rates.
The increasing number of public-private partnerships (PPPs) aimed at strengthening cardiovascular healthcare delivery is another significant opportunity for the MEA Vascular Stent Market. Governments across the region are increasingly collaborating with private healthcare providers, international organizations, and medical device manufacturers to expand access to advanced treatments such as vascular stenting.
In Saudi Arabia, for example, the Ministry of Health partnered with private hospitals and device companies to establish regional cardiovascular centers equipped with catheterization labs, significantly increasing the number of PCI procedures performed annually. These partnerships not only enhance procedural capacity but also encourage technology transfer and local manufacturing, reducing dependency on imports and lowering device costs.
The inconsistency in reimbursement policies across the region is one of the major challenges facing the MEA Vascular Stent Market. Unlike in more developed markets where standardized reimbursement frameworks exist, MEA countries have fragmented and often unpredictable reimbursement systems, particularly for high-cost medical devices such as drug-eluting stents (DES). According to the World Health Organization (WHO), reimbursement coverage for DES varies widely—from full coverage in select private insurance plans in the UAE and Saudi Arabia to limited or no coverage in public health systems in countries like Egypt and Nigeria.
In Saudi Arabia, while the Ministry of Health has made efforts to standardize reimbursement for cardiovascular procedures, coverage remains uneven across provinces. This lack of uniformity discourages device manufacturers from investing in market expansion and limits the adoption of advanced stent technologies, ultimately affecting patient outcomes and market growth.
The regulatory fragmentation and lengthy approval processes for medical devices is another pressing challenge in the MEA Vascular Stent Market. Unlike in more developed markets such as the United States or Europe, where regulatory pathways are standardized and well-established, MEA countries have varying regulatory frameworks that can delay market entry for new vascular stent technologies. According to the International Medical Device Regulators Forum (IMDRF), countries like Saudi Arabia, Egypt, and South Africa require separate and often redundant approval procedures, which can extend the time to market by 12–18 months.
The Saudi Food and Drug Authority (SFDA) and the South African Health Products Regulatory Authority (SAHPRA) are known for their rigorous and time-consuming evaluation processes. A 2023 report by the Gulf Medical Devices Association noted that the average time for approval of cardiovascular devices in Saudi Arabia is approximately 20 months, compared to 6–8 months in the European Union. This delay discourages international manufacturers from entering or expanding in the MEA market, limiting the availability of innovative stent technologies. Additionally, regulatory uncertainty in countries like Libya and Yemen has further hampered investment and product launches. These inefficiencies not only affect the pace of technological adoption but also reduce competition, leading to higher device prices and reduced patient access.
The coronary stents segment dominated the MEA Vascular Stent Market by accounting for a 56.4% of total volume in 2023. High prevalence of coronary artery disease (CAD) and the increasing number of percutaneous coronary interventions (PCIs) performed across the region is propelling the growth of coronary stents segment. In the Gulf Cooperation Council (GCC) countries, where healthcare infrastructure is more developed, the adoption of coronary stents has been robust. As per the Saudi Heart Association, over 80,000 PCIs were conducted in Saudi Arabia in 2022, with a significant proportion utilizing drug-eluting stents. These trends reflect the growing demand for coronary stents, supported by rising healthcare expenditure and expanding access to interventional cardiology services across the region.
The EVAR (Endovascular Aneurysm Repair) stent grafts segment represent the fastest-growing segment in the MEA Vascular Stent Market and is projected to expand at a CAGR of 12.1% from 2025 to 2033. The surge in growth is primarily driven by the increasing incidence of abdominal aortic aneurysms (AAAs) and the rising preference for minimally invasive vascular interventions. The adoption of EVAR procedures has been further accelerated by improvements in catheterization lab infrastructure and physician training in vascular interventions. Additionally, in Saudi Arabia and the UAE, government-backed initiatives have facilitated better access to vascular surgical care, supporting the uptake of EVAR stent grafts.
The Drug-Eluting Stents (DES) segment led the MEA Vascular Stent Market by accounting for 62.5% of total stent sales in 2024. The dominance of DES is primarily due to their superior clinical performance in reducing in-stent restenosis and improving long-term patient outcomes compared to bare-metal stents (BMS). The growing adoption of DES is supported by increasing awareness among interventional cardiologists regarding their benefits and the gradual expansion of reimbursement coverage in public healthcare systems.
The bioabsorbable stents segment is emerging as the fastest-growing segment in the MEA Vascular Stent Market and is projected to grow at a CAGR of 14.5% during the forecast period. Unlike traditional metal stents, bioabsorbable stents dissolve over time after supporting the artery, reducing long-term complications such as stent thrombosis and vessel rigidity. The expansion of this segment is also being driven by increased investment from major medical device manufacturers in clinical research and product development. Companies such as Abbott and Biotronik have launched pilot programs in the Middle East to evaluate the efficacy of bioabsorbable stents in local patient populations.
The balloon-expanding stents segment constituted the largest category in the MEA Vascular Stent Market by capturing a 67.5% of total volume in 2024. Their widespread use in coronary interventions, where precise deployment and high radial strength are critical is propelling the dominance of balloon-expanding stents segment. The preference for balloon-expanding stents is reinforced by their compatibility with a wide range of lesion types and their proven track record in clinical settings. Additionally, the availability of cost-effective stent variants from both global and regional manufacturers has supported their widespread adoption.
The self-expanding stents segment is emerging as the fastest-growing in the MEA Vascular Stent Market and is projected to grow at a CAGR of 12.8% from 2025 to 2033. These stents are increasingly used in peripheral vascular interventions, particularly in the treatment of iliac and femoral artery diseases. According to the South African Society of Cardiothoracic Surgeons, the number of peripheral interventions in South Africa increased by 40% between 2018 and 2022, with a growing share utilizing self-expanding stents due to their flexibility and adaptability in tortuous vessels. Technological advancements in stent design and material composition have also contributed to the rising adoption of self-expanding stents.
Saudi Arabia commanded the MEA Vascular Stent Market by accounting for a 25.3% of total revenue in 2024. As the region’s economic and healthcare leader, the country benefits from a well-developed network of cardiology centers and a high volume of percutaneous coronary interventions (PCIs). The Ministry of Health has made cardiovascular disease prevention a national priority, investing in hospital upgrades and expanding access to interventional cardiology services. The market is further supported by Vision 2030, a strategic framework aimed at improving healthcare infrastructure and increasing private sector participation. Additionally, the country has strengthened its regulatory framework through the Saudi Food and Drug Authority (SFDA), ensuring the availability of high-quality vascular devices.
The UAE is positioning itself as a major contributor in the region. The country has a highly developed healthcare system, particularly in Dubai and Abu Dhabi, where interventional cardiology services are well established. The government has made efforts to improve access to cardiovascular care through health insurance mandates and public-private partnerships. Additionally, the expansion of private healthcare providers and the presence of leading medical device manufacturers have strengthened the UAE’s market position. The country is also investing in digital health and telemedicine, enhancing post-operative monitoring and improving long-term patient management. These initiatives support the continued growth of the vascular stent market in the UAE.
South Africa holds a significant portion of the MEA Vascular Stent Market, which is driven by a relatively advanced healthcare system and a growing burden of cardiovascular diseases. The country has a well-established network of private and public hospitals, particularly in urban centers like Johannesburg and Cape Town, where interventional cardiology services are more accessible. The government has made efforts to improve cardiovascular care through the National Health Insurance (NHI) program, which aims to provide equitable access to essential medical services. Despite economic challenges, South Africa remains a key market for vascular stents due to its strong medical infrastructure and growing patient demand.
Egypt represents a notable share of the MEA Vascular Stent Market and is driven by a large patient pool and increasing awareness of cardiovascular diseases. The country has a growing number of interventional cardiology centers, particularly in Cairo and Alexandria, where PCI volumes have been rising steadily. The government has been working to expand access to cardiovascular care through public health initiatives and improved procurement processes. Additionally, the General Organization for Hospital Services (GOHS) has implemented cost-reduction strategies for stent procurement, making vascular interventions more affordable.
The Rest of MEA accounts for a decent portion of the regional vascular stent market, with Israel, Ethiopia, Kenya, and Sudan emerging as key contributors. Israel has one of the most advanced healthcare systems in the region, with high adoption rates of drug-eluting stents and a strong focus on research and innovation. In Ethiopia and Kenya, the market is growing due to increasing government investment in cardiovascular care and the expansion of private healthcare services. In Sudan, despite economic challenges, there has been a gradual increase in PCI procedures, supported by international aid and partnerships with regional healthcare providers.
Abbott Laboratories is a global leader in the vascular stent market and holds a strong presence in the MEA region. The company is widely recognized for its innovation in drug-eluting stents and bioresorbable vascular scaffolds. Abbott has strategically expanded its reach in the Middle East and parts of Africa through partnerships with regional healthcare providers, government collaborations, and investments in physician training programs. Its commitment to developing cost-effective and high-performance stent solutions has enabled it to maintain a competitive edge in both coronary and peripheral stent segments across the MEA market.
Medtronic is a dominant player in the MEA Vascular Stent Market, offering a comprehensive portfolio of coronary, peripheral, and aortic stent grafts. The company has focused on strengthening its distribution network and enhancing clinical education for healthcare professionals across the region. Medtronic collaborates with public health systems to improve access to advanced vascular interventions and supports regional research initiatives. Its emphasis on innovation, regulatory compliance, and localized product offerings has allowed it to establish a strong foothold in key MEA markets such as Saudi Arabia, the UAE, and South Africa.
Biotronik is a leading European-based cardiovascular device manufacturer with a growing influence in the MEA Vascular Stent Market. The company is known for its innovative stent technologies, including biodegradable polymer-coated and drug-eluting stents. Biotronik has invested heavily in clinical trials and physician training programs in the Middle East and North Africa, fostering strong relationships with interventional cardiologists. Its commitment to delivering high-performance, durable, and safe vascular solutions has helped it gain a loyal customer base across the region.
One of the primary strategies employed by key players in the MEA Vascular Stent Market is expanding regional distribution networks. Companies are strengthening their supply chains and collaborating with local distributors to ensure consistent product availability across both urban and rural healthcare facilities. This approach enhances accessibility and supports the timely delivery of stents, especially in public hospitals with high procedural volumes.
Another critical strategy is investing in clinical education and physician training. Market leaders are actively conducting workshops, certification programs, and live demonstrations to familiarize interventional cardiologists with the latest stent technologies. By building clinical confidence and trust, manufacturers can drive adoption and preference for their products in key procedures such as PCI and peripheral interventions.
Lastly, companies are engaging in strategic partnerships and collaborations with local governments, academic institutions, and healthcare providers. These alliances help in navigating regulatory landscapes, improving reimbursement frameworks, and aligning product development with regional healthcare needs, thereby solidifying long-term market presence and competitiveness.
Companies that have presence in the Middle East & Africa Vascular Stent Market profiled in the report are Medtronic, plc (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), BIOTRONIK SE & Co. KG (Germany), B. Braun Melsungen AG (Germany), Terumo Corporation (Japan), STENTYS SA (France), MicroPort Scientific Corporation (China), Meril Life Sciences Pvt. Ltd. (India), Vascular Concepts (India), W. L. Gore and Associates (U.S.), C. R. Bard (U.S.), Endologix, Inc. (U.S.), Lombard Medical Technologies (U.K.), Translumina GmbH (Germany), and JOTEC GmbH (Germany).
The MEA Vascular Stent Market features a competitive environment shaped by the presence of global medical device giants and a growing number of regional players. While multinational corporations dominate due to their extensive product portfolios, technological innovation, and strong brand recognition, local manufacturers are gradually gaining traction by offering cost-effective alternatives tailored to the needs of emerging markets. The market is characterized by a fragmented structure, with competition centered around product differentiation, pricing strategies, and localized service support.
A key differentiator among competitors is the ability to navigate diverse regulatory landscapes and establish strong distribution networks across the Middle East and Africa. Companies are increasingly focusing on physician education, clinical training, and strategic collaborations with public healthcare systems to enhance product adoption. Additionally, the expansion of private healthcare infrastructure and growing investments in telemedicine are creating new opportunities for market players to expand their reach. As awareness of cardiovascular diseases increases and healthcare access improves, competition is expected to intensify, prompting companies to invest in innovation and localized market development strategies to maintain a sustainable foothold in the region.
This research report on the Middle East and Africa Vascular Stent Market has been segmented and sub-segmented into the following categories.
By Product
By Type
By Mode of Delivery
By Material
By End User
By Country
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 1600
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region